VBI Vaccines Initiates Restructuring Proceedings Under CCAA to ...
CAMBRIDGE, Mass., July 30, 2024 -- (BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful …
VBI Vaccines Restructures and Acquired by K2 VBI Trust
Jan 3, 2025 · VBI Vaccines Inc. is a biopharmaceutical company that develops vaccine candidates using innovative virus-like particles (VLP) technologies, including a proprietary …
Brii Biosciences buying VBI Vaccine’s hepatitis B therapy
15 hours ago · Brii Biosciences, a Durham biotechnology company with global headquarters in China, plans to buy the intellectual property and other remaining assets of a defunct …
VBI Vaccines Announces Completion of Sales Process to K2
Jan 3, 2025 · VBI Vaccines Inc. ("VBI" or the "Company") today announced, that, in connection with its creditor protection proceedings under the Companies' Creditors Arrangement Act …
VBI Vaccines Provides an Update on its Restructuring Proceedings …
CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ - VBI Vaccines Inc. ("VBI" or the "Company") today provided an update on the restructuring proceedings announced on July 30, 2024. …
Hepatitis B Vaccine PreHevbrio Recalled Due to Company …
Nov 19, 2024 · VBI Vaccines has issued a voluntary nationwide recall of all remaining PreHevbrio ® (hepatitis B vaccine [recombinant]) due to the discontinuation of company operations.
VBI Vaccines Announces Completion of Sales Process to K2 - PR …
CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ - VBI Vaccines Inc. ("VBI" or the "Company") today announced, that, in connection with its creditor protection proceedings under the …
VBI recalls PreHevbrio and winds down operations
Nov 19, 2024 · Massachusetts, USA-based firm VBI Vaccines (Nasdaq: VBIV) has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy …
Why Is VBI Vaccines (VBIV) Stock Up 62% Today? - InvestorPlace
Aug 6, 2024 · VBI Vaccines (NASDAQ:VBIV) stock is rising higher on Tuesday after the commercial-stage biopharmaceutical company filed for bankruptcy last week.
Brii buys further into VBI therapy, expanding hepatitis B partnership
Jul 6, 2023 · Brii Biosciences has acquired broader rights to an experimental immunotherapy for hepatitis B developed by VBI Vaccines, as well as to the latter company’s approved hepatitis B …
- Some results have been removed